FLT3

Jorge Cortes | EHA 2018 | Highlights of the randomized phase III QuANTUM-R study

L:

At the 23rd Congress of the European Hematology Association (EHA), Jorge Cortes (member of our North American Steering Committee) from the MD Anderson Cancer Center, Houston, TX, discuss highlights of the randomized phase III QuANTUM-R study. Quizartinib significantly prolongs OS in RR FLT3-ITD acute myeloid leukemia (AML) patients compared to standard chemotherapy.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF